Preclinical characterization of IPH45, a novel topoisomerase I inhibitor ADC targeting Nectin-4 for the treatment of Nectin-4 expressing tumors

被引：1
|
作者：
Remark, Romain
Bonnafous, Cecile
Chiossone, Laura
Soulas, Caroline
Perrier, Cyril
Habif, Guillaume
Bokobza, Sivan
Maguer, Aurelie
Courtois, Rachel
Lopez, Julie
Fenaux, Gregory
Benac, Olivier
Carrette, Barbara
Letay-Drouet, Robin
Bonifay, Raja
Augier, Severine
Simon, Lea
Rossi, Benjamin
Morel, Ariane
Represa, Agnes
Beltraminelli, Nicola
Morel, Yannis
Paturel, Carine
Vivier, Eric
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-6582
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6582
引用
收藏
页数：2
相关论文
共 36 条
  • [31] Preclinical development of YL202, a novel HER3-targeting antibody-drug conjugate (ADC) with novel DNA topoisomerase I inhibitor for treatment of solid tumors
    Xu, Jian
    Zong, Qing
    Zhu, Liang
    Liu, Qigang
    Stann, Sasha
    Cai, Jiaqiang
    CANCER RESEARCH, 2023, 83 (07)
  • [32] BT8009-100 phase I/II study of novel bi-cyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies associated with nectin-4 expression
    McKean, Meredith
    Baldini, Capucine
    Verlingue, Loic
    Doger, Bernard
    Falchook, Gerald
    Italiano, Antoine
    Lostes, Julia
    Reig, Oscar
    Watson, Roshawn
    Hazard, Sebastien
    Smethurst, Dominic
    Fulci, Giulia
    Xu, Hongmei
    Jeffery, Phil
    Lee, Kevin
    Brana, Irene
    Cousin, Sophie
    Fontana, Elisa
    Arkenau, Hendrik-Tobias
    CANCER RESEARCH, 2022, 82 (12)
  • [33] Efficacy and safety of 9 MW2821, an antibody-drug conjugate targeting Nectin-4 monotherapy, in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, phase I/II study
    Yang, Huijuan
    Zhang, Jian
    Liu, Rujiao
    Gao, Shuiping
    Lou, Hanmei
    Li, Guiling
    Bu, Hualei
    Li, Rong
    Wang, Shanbing
    Shen, Shujing
    Zhang, Mingjun
    Wang, Peipei
    Feng, Zhe
    Chu, Nan
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S22 - S23
  • [34] BT8009-100: A phase I/II study of novel bicyclic peptide and MMAE conjugate BT8009 in patients (pts) with advanced malignancies associated with nectin-4 expression, including urothelial cancer (UC).
    Baldini, Capucine
    Goldschmidt, Vincent
    Brana, Irene
    Doger, Bernard
    Italiano, Antoine
    Cousin, Sophie
    Falchook, Gerald Steven
    Necchi, Andrea
    Reig, Oscar
    Carter, Louise
    Fontana, Elisa
    Verlingue, Loic
    Hazard, Sebastien
    Dickson, Amy
    Xu, Cong
    Xu, Hongmei
    Sharma, Rajiv
    Smethurst, Dominic
    McKean, Meredith
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [35] Preclinical development of YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) with novel topoisomerase I inhibitor-based linker- payload for treatment of solid tumors
    Xiao, Liang
    Lian, Wei
    Liu, Qigang
    Zong, Qing
    Song, Shuai
    Stann, Sasha
    Cai, Jiaqiang
    Xue, Tongtong
    CANCER RESEARCH, 2024, 84 (06)
  • [36] Preclinical efficacy and safety of M9140, a novel antibody-drug conjugate (ADC) with topoisomerase 1 (TOP1) inhibitor payload targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing colorectal tumors
    Raab-Westphal, Sabine
    Hart, Felix
    Sloot, Willem
    Shan, Min
    Rasche, Nicolas
    Amendt, Christiane
    Anderl, Jan
    CANCER RESEARCH, 2024, 84 (06)
1234